Epithelioid Hemangioendothelioma — Trials

Epithelioid Hemangioendothelioma — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 4
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: BridGene Biosciences Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01154452	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	completed	Phase 1 / Phase 2	78	National Cancer Institute (NCI)NIH	1	Aug 15, 2018	clinicaltrials

Data updated 23 days agoSource updated Aug 15, 2018source: clinicaltrials